Cargando…
A Metabolic Signature of Hereditary Transthyretin Amyloidosis: A Pilot Study
Hereditary transthyretin amyloidosis is the most common form of hereditary amyloidosis, with an autosomal dominant inheritance and a variable penetrance. ATTRv amyloidosis can present as a progressive, axonal sensory autonomic and motor neuropathy or as an infiltrative cardiomyopathy. The definition...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783933/ https://www.ncbi.nlm.nih.gov/pubmed/36555770 http://dx.doi.org/10.3390/ijms232416133 |
_version_ | 1784857691966930944 |
---|---|
author | Luigetti, Marco Guglielmino, Valeria Romano, Angela Sciarrone, Maria Ausilia Vitali, Francesca Sabino, Andrea Gervasoni, Jacopo Primiano, Aniello Santucci, Lavinia Moroni, Rossana Primiano, Guido |
author_facet | Luigetti, Marco Guglielmino, Valeria Romano, Angela Sciarrone, Maria Ausilia Vitali, Francesca Sabino, Andrea Gervasoni, Jacopo Primiano, Aniello Santucci, Lavinia Moroni, Rossana Primiano, Guido |
author_sort | Luigetti, Marco |
collection | PubMed |
description | Hereditary transthyretin amyloidosis is the most common form of hereditary amyloidosis, with an autosomal dominant inheritance and a variable penetrance. ATTRv amyloidosis can present as a progressive, axonal sensory autonomic and motor neuropathy or as an infiltrative cardiomyopathy. The definition of biomarkers for the early diagnosis of ATTRv is particularly important in the current era of emerging treatments. In this sense, metabolomics could be an instrument able to provide metabolic profiles with their related metabolic pathways, and we would propose them as possible fluid biomarkers. The aim of this study is to identify altered metabolites (free fatty acids and amino acids) in subjects with a confirmed pathogenic TTR variant. Out of the studied total free fatty acids and amino acids, the serum values of palmitic acid are significantly lower in the ATTRv patients compared to the recruited healthy subjects. The metabolic remodeling identified in this neurogenetic disorder could be the manifestation of pathophysiological processes of the disease, such as mitochondrial dysfunction and neuroinflammation, and contribute to explaining some of its clinical manifestations. |
format | Online Article Text |
id | pubmed-9783933 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97839332022-12-24 A Metabolic Signature of Hereditary Transthyretin Amyloidosis: A Pilot Study Luigetti, Marco Guglielmino, Valeria Romano, Angela Sciarrone, Maria Ausilia Vitali, Francesca Sabino, Andrea Gervasoni, Jacopo Primiano, Aniello Santucci, Lavinia Moroni, Rossana Primiano, Guido Int J Mol Sci Communication Hereditary transthyretin amyloidosis is the most common form of hereditary amyloidosis, with an autosomal dominant inheritance and a variable penetrance. ATTRv amyloidosis can present as a progressive, axonal sensory autonomic and motor neuropathy or as an infiltrative cardiomyopathy. The definition of biomarkers for the early diagnosis of ATTRv is particularly important in the current era of emerging treatments. In this sense, metabolomics could be an instrument able to provide metabolic profiles with their related metabolic pathways, and we would propose them as possible fluid biomarkers. The aim of this study is to identify altered metabolites (free fatty acids and amino acids) in subjects with a confirmed pathogenic TTR variant. Out of the studied total free fatty acids and amino acids, the serum values of palmitic acid are significantly lower in the ATTRv patients compared to the recruited healthy subjects. The metabolic remodeling identified in this neurogenetic disorder could be the manifestation of pathophysiological processes of the disease, such as mitochondrial dysfunction and neuroinflammation, and contribute to explaining some of its clinical manifestations. MDPI 2022-12-17 /pmc/articles/PMC9783933/ /pubmed/36555770 http://dx.doi.org/10.3390/ijms232416133 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Luigetti, Marco Guglielmino, Valeria Romano, Angela Sciarrone, Maria Ausilia Vitali, Francesca Sabino, Andrea Gervasoni, Jacopo Primiano, Aniello Santucci, Lavinia Moroni, Rossana Primiano, Guido A Metabolic Signature of Hereditary Transthyretin Amyloidosis: A Pilot Study |
title | A Metabolic Signature of Hereditary Transthyretin Amyloidosis: A Pilot Study |
title_full | A Metabolic Signature of Hereditary Transthyretin Amyloidosis: A Pilot Study |
title_fullStr | A Metabolic Signature of Hereditary Transthyretin Amyloidosis: A Pilot Study |
title_full_unstemmed | A Metabolic Signature of Hereditary Transthyretin Amyloidosis: A Pilot Study |
title_short | A Metabolic Signature of Hereditary Transthyretin Amyloidosis: A Pilot Study |
title_sort | metabolic signature of hereditary transthyretin amyloidosis: a pilot study |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783933/ https://www.ncbi.nlm.nih.gov/pubmed/36555770 http://dx.doi.org/10.3390/ijms232416133 |
work_keys_str_mv | AT luigettimarco ametabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT guglielminovaleria ametabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT romanoangela ametabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT sciarronemariaausilia ametabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT vitalifrancesca ametabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT sabinoandrea ametabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT gervasonijacopo ametabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT primianoaniello ametabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT santuccilavinia ametabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT moronirossana ametabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT primianoguido ametabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT luigettimarco metabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT guglielminovaleria metabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT romanoangela metabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT sciarronemariaausilia metabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT vitalifrancesca metabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT sabinoandrea metabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT gervasonijacopo metabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT primianoaniello metabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT santuccilavinia metabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT moronirossana metabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy AT primianoguido metabolicsignatureofhereditarytransthyretinamyloidosisapilotstudy |